pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene trial registry — 16 ClinicalTrials.gov studies with program phase, status, and indication context.
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
BeiGene clinical trials
Registry index of 16 ClinicalTrials.gov studies linked to BeiGene programs — each row shows trial ID, program name, phase, status, and indication.
BeiGene trial registry — 16 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for BeiGene.
-
BGB-A317-A3055-101 — Phase 1
Clinical update -
BGB-A317-A1217-302 — Phase 3
Clinical update -
BGB-21447-101 — Phase 1
Clinical update -
Pamiparib capsule — Phase 3
Clinical update -
OBINUTUZUMAB, Zanubrutinib — Phase 2
Clinical update -
BGB DXP593 — Phase 1
Clinical update -
Surzebiclimab — Phase 2
Clinical update -
BGB-3111 — Phase 3
Clinical update
Trial registry
-
CTIS ↗ - 2023-507317-10-00CTIS ↗
BGB-A317-A1217-302
Locally advanced, unresectable, or metastatic non small cell lung cancer
-
CTIS ↗ -
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT03744468CT.gov ↗
Surzebiclimab
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗